Macrolide resistance and molecular typing of Mycoplasma pneumoniae infections during a 4 year period in Spain

J Antimicrob Chemother. 2020 Oct 1;75(10):2752-2759. doi: 10.1093/jac/dkaa256.

Abstract

Background: Mycoplasma pneumoniae (MP) causes community-acquired pneumonia affecting mainly children, and tends to produce cyclic outbreaks. The widespread use of macrolides is increasing resistance rates to these antibiotics. Molecular tools can help in diagnosis, typing and resistance detection, leading to better patient management.

Objectives: To assess the MP genotypes and resistance pattern circulating in our area while comparing serological and molecular diagnosis of MP.

Methods: Molecular and serological diagnosis of MP was performed in 821 samples collected in Badalona (Barcelona, Spain) from 2013 to 2017. Multiple locus variable number tandem repeat analysis (MLVA) and macrolide resistance detection by pyrosequencing were performed in those cases positive by PCR. Presence of respiratory viruses and relevant clinical data were also recorded.

Results: MP was detected in 16.8% of cases by PCR, with an overall agreement with serology of 76%. Eleven different MLVA types were identified, with 4-5-7-2 (50.1%) and 3-5-6-2 (29.2%) being the most abundant, with the latter showing a seasonal increase during the study. A total of 8% of the strains harboured a point substitution associated with macrolide resistance, corresponding mainly to an A2063G 23S rRNA mutation and directly related to previous macrolide therapy. Analysis of respiratory viruses showed viral coinfections in most cases.

Conclusions: Serological and molecular tools combined could improve MP diagnosis and the analysis of its infection patterns. Macrolide resistance is associated with previous therapy. Given that MP pneumonia usually resolves spontaneously, it should be reconsidered whether antibiotic treatment is suitable for all cases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Child
  • Drug Resistance, Bacterial / drug effects
  • Female
  • Humans
  • Macrolides / pharmacology
  • Male
  • Molecular Typing
  • Mycoplasma pneumoniae / drug effects
  • Mycoplasma pneumoniae / genetics
  • Pneumonia, Mycoplasma* / drug therapy
  • Pneumonia, Mycoplasma* / epidemiology
  • RNA, Ribosomal, 23S / genetics
  • Spain / epidemiology

Substances

  • Anti-Bacterial Agents
  • Macrolides
  • RNA, Ribosomal, 23S